The Use of Trimethoprim-Sulfamethoxazole for Serious MRSA Infections
Document Type
Article
Publication Date
10-1-2005
Description
Vancomycin has been considered first-line treatment for bacteremia caused by methicillin-resistant Staphylococcus aureus (MRSA) despite treatment failures in up to 20% of patients with MRSA bacteremia secondary to endocarditis. However, trimethoprim-sulfamethoxazole (TMP-SMX) is as effective as vancomycin for the management of MRSA bacteremia. secondary to endocarditis in injection drug users. We report the successful management of a left ventricular assist device-related MRSA infection with persistent MRSA bacteremia that failed to respond to vancomycin, linezolid, and quinupristin/dalfopristin but did respond to TMP-SMX.
Citation Information
Shams, Wael E.; McCormick, Malkanthie; Rapp, Robert P.; and Evans, Martin E.. 2005. The Use of Trimethoprim-Sulfamethoxazole for Serious MRSA Infections. Infections in Medicine. Vol.22(10). 507-510. ISSN: 0749-6524